This clinical-grade reference guide provides pulmonologists, primary care physicians, and respiratory therapists with an evidence-ranked management framework for non-cystic fibrosis bronchiectasis, enabling precise etiology screening, systematic airway clearance, and structured antibiotic stewardship.
Non-cystic fibrosis bronchiectasis is characterized by chronic bronchial inflammation and recurrent respiratory infections. However, certain clinical presentations indicate rapid disease progression, severe systemic compromise, or life-threatening hemorrhage, requiring immediate hospitalization, diagnostic escalation, or emergency intensive care. Clinicians and clinical coordinators must screen for and prioritize the following red flags:
The pathophysiology of non-cystic fibrosis bronchiectasis is historically conceptualized using Cole's Vicious Circle Hypothesis [4][5]. This model explains a permanent, self-perpetuating loop of impaired mucociliary clearance, chronic bronchial inflammation, bacterial colonization/infection, and progressive structural tissue destruction.
┌────────────────────────────────────────────────────────┐
│ Impaired Mucociliary Clearance │
│ (Genetic, post-infectious, immune) │
└───────────────────────────┬────────────────────────────┘
▼
┌────────────────────────────────────────────────────────┐
│ Persistent Bacterial Colonization │
│ (H. influenzae, P. aeruginosa) │
└───────────────────────────┬────────────────────────────┘
▼
┌────────────────────────────────────────────────────────┐
│ Chronic Neutrophilic Inflammation │
│ (Infiltration, elastase & protease release) │
└───────────────────────────┬────────────────────────────┘
▼
┌────────────────────────────────────────────────────────┐
│ Airway Wall Destruction │
│ (Elastin degradation, irreversible dilation) │
└───────────────────────────┬────────────────────────────┘
▲
└────────────────────────────┘
Impaired clearance allows mucus to stagnate in the bronchi, creating a niche for chronic bacterial colonization. In response, a massive influx of neutrophils occurs. However, these neutrophils fail to eliminate the bacteria, instead releasing high concentrations of host-derived proteases (especially neutrophil elastase) and reactive oxygen species. These inflammatory mediators degrade elastin and other structural components of the bronchial wall, leading to irreversible airway dilation, loss of ciliary function, and further mucus retention [6].
Anatomically, this process results in the irreversible dilatation and distortion of medium-sized bronchi [7]. This structural change is diagnostic on High-Resolution Computed Tomography (HRCT) of the chest, which represents the gold standard for confirmation [4:1][5:1]. Key radiographic criteria include:
Spirometry and pulmonary function tests (PFTs) in stable patients typically demonstrate an obstructive pattern, characterized by a reduction in FEV1 (forced expiratory volume in one second), FVC (forced vital capacity), and an FEV1/FVC ratio [4:2][5:2], though mixed or restrictive patterns may develop in advanced stages with parenchymal involvement [5:3].
Identifying the underlying cause of bronchiectasis is critical, as approximately 38% of cases are idiopathic based on European registry data [8], though up to 50% of cases are reported as idiopathic in other cohorts [9]. However, a significant proportion of patients have "treatable traits" or specific etiologies that alter management [4:3][5:4][10]. Guidelines recommend a systematic etiology screen at baseline, with initial screening for immunoglobulins, ABPA, and sputum mycobacteria strongly supported by clinical evidence [3:2]. Other specific investigations are carried out as established clinical practice standards to target underlying causes:
The therapeutic management of bronchiectasis focuses on breaking the vicious pathophysiological cycle: enhancing mucociliary clearance, suppressing chronic bacterial infection, preventing acute exacerbations, and managing progressive airflow limitation. Interventions are ranked below based on the GRADE framework and consensus guidelines.
| Intervention | Evidence Level | What to do | Clinical Findings & Notes |
|---|---|---|---|
| Physical Airway Clearance Techniques (ACTs) | Low [1:1][2:1] | Teach and perform twice-daily sessions (e.g., Active Cycle of Breathing Techniques, OPEP devices like Acapella/Flutter) [1:2]. | Significantly increases daily sputum expectoration, eases coughing difficulty, reduces pulmonary hyperinflation, and improves health-related quality of life (HRQoL) [1:3][2:2]. Pause during active major hemoptysis as a standard clinical safety consensus. Note: Although international clinical guidelines strongly recommend ACTs as standard care, the supporting RCT evidence base remains limited in GRADE quality due to small study sizes. |
| Long-Term Prophylactic Macrolides (Azithromycin/Erythromycin) | Moderate [14] | Consider for patients with exacerbations/year [12:1][5:6]. Sputum culture to rule out NTM is recommended [3:6], and ECG screening represents standard safety practice. | Reduces exacerbation frequency by up to 66% (OR 0.34) and improves SGRQ scores [14:1]. Carries risk of inducing macrolide resistance in NTM or other pathogens [14:2], and potential QTc prolongation as a standard safety consideration. |
| Inhaled Hyperosmolar Agents (HTS 3–6% / Mannitol) | Moderate [6:1] | Nebulize 3–6% Hypertonic Saline (HTS) or use dry-powder Mannitol twice daily prior to ACT sessions [6:2]. | Mannitol increases time to first exacerbation (median 165 vs 124 days) [6:3]. Hypertonic saline improves dynamic lung volumes and reduces exacerbations in pediatric populations [15], but the Cochrane review [6:4] found that evidence for its efficacy in adults remains currently inconclusive. |
| Pseudomonas aeruginosa Eradication Therapy | Moderate [13:2] | Initiate dual combined oral/intravenous and inhaled antibiotic therapy upon first-time isolation of P. aeruginosa in sputum [12:2][13:3]. | Achieves a 40–48% eradication rate at 12 months, preventing chronic colonization which is associated with rapid FEV1 decline and increased mortality [13:4]. |
| Pulmonary Rehabilitation & Aerobic Exercise | Low to Moderate [16] | Enroll in a 6–8 week supervised exercise training program of aerobic and resistance training [16:1]. | Improves functional exercise capacity (6MWD mean difference of 42m, ISWD mean difference of 87m) and health-related quality of life immediately following the intervention [16:2]. |
| Vaccinations (Influenza, Pneumococcal, COVID-19) | Low to Moderate [12:3][5:7] | Administer annual influenza and pneumococcal conjugate (PCV15/20) / polysaccharide (PPSV23) vaccines [12:4][5:8], and the COVID-19 series (as a general clinical recommendation). | Standard clinical practice to prevent secondary viral-induced and bacterial-induced acute exacerbations [12:5][5:9], with COVID-19 vaccination serving as a general clinical recommendation. |
| Inhaled Corticosteroids (ICS) without Comorbid Asthma | Low (Not Recommended) [17][18] | Avoid routine prescription of ICS unless a concurrent diagnosis of asthma is established [17:1]. | Cochrane reviews show no benefit in reducing exacerbations or lung function decline [17:2]. Real-world EMBARC registry data reveals widespread inappropriate overuse of ICS in patients without asthma [18:1], while increased risk of pneumonia remains a general clinical concern with inappropriate corticosteroid use. |
| Recombinant Human DNase (rhDNase) | Low (Strongly Contraindicated) [7:1][19] | Do not prescribe to patients with non-CF bronchiectasis [7:2][19:1]. | Clinically proven to increase exacerbation frequency and negatively impact lung function (FEV1) in non-CF bronchiectasis patients, despite benefits in cystic fibrosis [7:3][19:2]. While the GRADE evidence quality is low, the clinical consensus against its use is strong due to demonstrated harm. |
Physical airway clearance is the non-pharmacological cornerstone of bronchiectasis management. It facilitates the clearance of secretions, reduces mucus plugging, and interrupts the inflammatory cascade [1:4][2:3]. Despite its clinical importance, European observational registry data indicates that only approximately 52% of patients with bronchiectasis regularly use airway clearance management [20].
Antibiotic therapy is primary in managing both acute exacerbations and chronic bacterial load, but must be balanced against the risk of driving microbial resistance [14:3][24]. Currently, there is a lack of comparative evidence regarding continuous versus intermittent antibiotic regimens; a Cochrane systematic review comparing these two approaches identified zero eligible randomized controlled trials [25].
Pseudomonas aeruginosa is associated with poor clinical outcomes, rapid lung function decline, and increased mortality [4:8][5:14][13:5]. Its management requires a dual approach:
To understand how to perform, interpret, and track annual pulmonary function metrics for bronchiectasis monitoring, see the Spirometry and Lung-Function Testing guide.
Longevipedia pages are AI-updated and human-reviewed. We prioritize human evidence, cite claims, and update pages when the evidence changes.
Lee AL, Burge AT, Holland AE. Airway clearance techniques for bronchiectasis. Cochrane Database of Systematic Reviews. 2015;11:CD008351. https://pubmed.ncbi.nlm.nih.gov/26591003/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Muñoz G, de Gracia J, Buxó M, et al. Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial. European Respiratory Journal. 2018;51(1):1701509. https://pubmed.ncbi.nlm.nih.gov/29326318/ ↩︎ ↩︎ ↩︎ ↩︎
Mosgrove E, Kocks JW, Kompatsiari E, et al. The European respiratory society guideline for adult bronchiectasis 2025: summary and implementation guide for primary care. NPJ Primary Care Respiratory Medicine. 2026;36:12. https://pubmed.ncbi.nlm.nih.gov/42259823/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal. 2017;50(3):1700629. https://pubmed.ncbi.nlm.nih.gov/28889110/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1-69. https://pubmed.ncbi.nlm.nih.gov/30545985/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Hart A, Sugumar K, Milan SJ. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database of Systematic Reviews. 2014;5:CD008349. https://pubmed.ncbi.nlm.nih.gov/24817558/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Wilkinson M, Sugumar K, Milan SJ. Mucolytics for bronchiectasis. Cochrane Database of Systematic Reviews. 2014;5:CD001287. https://pubmed.ncbi.nlm.nih.gov/24789119/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Chalmers JD, Polverino E, Crichton ML, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). The Lancet Respiratory Medicine. 2023;11(7):637-649. https://pubmed.ncbi.nlm.nih.gov/37105206/ ↩︎
Sidhu MK, Mandal P, Hill AT. Developing drug therapies in bronchiectasis. Expert Opinion on Investigational Drugs. 2015;24(2):231-244. https://pubmed.ncbi.nlm.nih.gov/25307313/ ↩︎
Lee AL, Spinou A, Basavaraj A. Addressing treatable traits in bronchiectasis through non-pharmacological therapies: a narrative review. Journal of Thoracic Disease. 2025;17(6):1024-1038. https://pubmed.ncbi.nlm.nih.gov/40688306/ ↩︎ ↩︎
Shoemark A, Rubbo B, Legendres M, et al. European Respiratory Society and American Thoracic Society guidelines for the diagnosis of primary ciliary dyskinesia. European Respiratory Journal. 2025;41005984. https://pubmed.ncbi.nlm.nih.gov/41005984/ ↩︎
Chalmers JD, Haworth CS, Flume P, et al. European Respiratory Society clinical practice guideline for the management of adult bronchiectasis. European Respiratory Journal. 2025;41016738. https://pubmed.ncbi.nlm.nih.gov/41016738/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Conceição M, Shteinberg M, Goeminne PC, et al. Eradication treatment for Pseudomonas aeruginosa infection in adults with bronchiectasis: a systematic review and meta-analysis. European Respiratory Review. 2024;33:230114. https://pubmed.ncbi.nlm.nih.gov/38296344/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kelly C, Chalmers JD, Crossingham I, et al. Macrolide antibiotics for bronchiectasis. Cochrane Database of Systematic Reviews. 2018;3:CD012406. https://pubmed.ncbi.nlm.nih.gov/29543980/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Anuradha KWDA, Gunathilaka PKG, Wickramasinghe VP. Effectiveness of hypertonic saline nebulization in airway clearance in children with non-cystic fibrosis bronchiectasis: A randomized control trial. Pediatric Pulmonology. 2021;56(2):415-423. https://pubmed.ncbi.nlm.nih.gov/33295693/ ↩︎
Lee AL, Gordon CS, Osadnik CR, et al. Exercise training for bronchiectasis. Cochrane Database of Systematic Reviews. 2021;4:CD013110. https://pubmed.ncbi.nlm.nih.gov/33822364/ ↩︎ ↩︎ ↩︎ ↩︎
Kapur N, Petsky HL, Bell S. Inhaled corticosteroids for bronchiectasis. Cochrane Database of Systematic Reviews. 2018;5:CD000996. https://pubmed.ncbi.nlm.nih.gov/29766487/ ↩︎ ↩︎ ↩︎ ↩︎
Pollock J, Polverino E, Dhar R, et al. Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC). Thorax. 2025;80:1-12. https://pubmed.ncbi.nlm.nih.gov/40122611/ ↩︎ ↩︎ ↩︎
Welsh EJ, Evans DJ, Fowler SJ. Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews. 2015;7:CD011202. https://pubmed.ncbi.nlm.nih.gov/26171905/ ↩︎ ↩︎ ↩︎ ↩︎
Spinou A, EMBARC Registry Investigators. Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC). European Respiratory Journal. 2024;63:2301824. https://pubmed.ncbi.nlm.nih.gov/38609097/ ↩︎
Patterson JE, Bradley JM, Hewitt O. Airway clearance in bronchiectasis: a randomized crossover trial of active cycle of breathing techniques versus Acapella. Respiration. 2005;72(3):239-244. https://pubmed.ncbi.nlm.nih.gov/15942291/ ↩︎ ↩︎
Patterson JE, Hewitt O, Kent L. Acapella versus 'usual airway clearance' during acute exacerbation in bronchiectasis: a randomized crossover trial. Chronic Respiratory Disease. 2007;4(2):67-74. https://pubmed.ncbi.nlm.nih.gov/17621572/ ↩︎
Patterson JE, Bradley JM, Elborn JS. Airway clearance in bronchiectasis: a randomized crossover trial of active cycle of breathing techniques (incorporating postural drainage and vibration) versus test of incremental respiratory endurance. Chronic Respiratory Disease. 2004;1(3):127-137. https://pubmed.ncbi.nlm.nih.gov/16281653/ ↩︎
Spencer S, Donovan T, Chalmers JD. Intermittent prophylactic antibiotics for bronchiectasis. Cochrane Database of Systematic Reviews. 2022;1:CD013254. https://pubmed.ncbi.nlm.nih.gov/34985761/ ↩︎
Donovan T, Felix LM, Chalmers JD. Continuous versus intermittent antibiotics for bronchiectasis. Cochrane Database of Systematic Reviews. 2018;6:CD012733. https://pubmed.ncbi.nlm.nih.gov/29860722/ ↩︎
Cox NS, Dal Corso S, Hansen H, et al. Telerehabilitation for chronic respiratory disease. Cochrane Database of Systematic Reviews. 2021;1:CD013040. https://pubmed.ncbi.nlm.nih.gov/33511633/ ↩︎
Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respiratory Research. 2018;5(1):e000374. https://pubmed.ncbi.nlm.nih.gov/30687502/ ↩︎ ↩︎